Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
09/19/16Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016Printer Friendly Version
09/12/16Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and Substance Use DisordersPrinter Friendly Version
09/06/16Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare ConferencePrinter Friendly Version
08/08/16Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA® for Treatment of SchizophreniaPrinter Friendly Version
07/28/16Alkermes plc Reports Second Quarter 2016 Financial ResultsPrinter Friendly Version
07/21/16Alkermes to Host Conference Call to Discuss Second Quarter 2016 Financial ResultsPrinter Friendly Version
06/01/16Alkermes’ Corporate Presentation to be Webcast at the Goldman Sachs 37th Annual Global Healthcare ConferencePrinter Friendly Version
05/26/16Alkermes Appoints Nancy Snyderman, M.D., to Board of DirectorsPrinter Friendly Version
05/25/16Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230Printer Friendly Version
05/24/16Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology Annual MeetingPrinter Friendly Version
04/28/16Alkermes plc Reports First Quarter 2016 Financial ResultsPrinter Friendly Version
04/28/16Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1 ResultsPrinter Friendly Version
04/21/16Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial ResultsPrinter Friendly Version
03/31/16Study on Extended-Release Naltrexone in Opioid-Dependent Patients Involved in Criminal Justice System Published in the New England Journal of MedicinePrinter Friendly Version
03/28/16Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research Society ConferencePrinter Friendly Version
03/09/16Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare ConferencePrinter Friendly Version
03/01/16Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 36th Annual Health Care ConferencePrinter Friendly Version
02/25/16Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and Provides Financial Expectations for 2016Printer Friendly Version
02/25/16Alkermes Announces Positive Topline Results From Clinical Study of Two-Month Dosing Option of ARISTADA® for Treatment of SchizophreniaPrinter Friendly Version
02/18/16Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial ResultsPrinter Friendly Version
02/10/16Alkermes Announces Initiation of Second Phase 3 Study of ALKS 3831 for SchizophreniaPrinter Friendly Version
02/02/16Alkermes’ Corporate Presentation to be Webcast at Two Upcoming ConferencesPrinter Friendly Version
01/25/16Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119Printer Friendly Version
01/21/16Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive DisorderPrinter Friendly Version
01/05/16Alkermes’ Corporate Presentation to be Webcast at the 34th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version

Other Resources

Email Alerts

Stay in Touch with Alkermes